In a report released on October 8, Brian Abrahams from RBC Capital maintained a Buy rating on Karyopharm Therapeutics. The company’s shares closed yesterday at $5.82.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Abrahams is a 3-star analyst with an average return of 2.4% and a 46.12% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Gilead Sciences, and PTC Therapeutics.
Karyopharm Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.80, representing a 171.48% upside. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $21.00 price target.
The company has a one-year high of $16.96 and a one-year low of $3.51. Currently, Karyopharm Therapeutics has an average volume of 221.2K.
Read More on KPTI:
Disclaimer & DisclosureReport an Issue
- Karyopharm price target lowered to $21 from $25 at Baird
- Karyopharm Therapeutics: Strategic Financing Extends Cash Runway Amid Cautious Hold Rating
- Karyopharm price target lowered to $6 from $8 at Leerink
- Morning Movers: AST SpaceMobile jumps after direct-to-cellular pact with Verizon
- Karyopharm Secures $100M Financing for Clinical Trials
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
